Metsera’s Cutting-Edge Pipeline
Founded in 2022 and headquartered in New York City, Metsera has quickly emerged as a biotech force. Its portfolio features oral and injectable incretin and nonincretin therapies, including promising combination treatments. With four clinical-stage programs and a slew of earlier candidates—such as long-acting GLP-1 receptor agonists designed for weekly or monthly dosing—Metsera has positioned itself at the vanguard of next-generation obesity treatments.
“Obesity is a large and growing space with over 200 associated health conditions,” Pfizer CEO Albert Bourla said. “This acquisition propels Pfizer into a key therapeutic area while aligning with our mission to invest in the most impactful opportunities.”
Incretin-based drugs mimic natural hormones that regulate appetite and blood sugar, while nonincretin therapies explore alternative pathways to tackle weight management and related diseases. Together, they provide Pfizer multiple avenues to revolutionize treatment.
